Abstract
A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.
| Original language | Italian |
|---|---|
| Pages (from-to) | 143-152 |
| Number of pages | 10 |
| Journal | Gazzetta Medica Italiana |
| Volume | 141 |
| Issue number | 4 |
| Publication status | Published - 1982 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL. / Palmieri, G.; Perego, M.; Baldini, I. M.
In: Gazzetta Medica Italiana, Vol. 141, No. 4, 1982, p. 143-152.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - VALUTAZIONE DELL'AGGREGAZIONE PIASTRINICA DI ALCUNI PARAMETRI EMOCOAGULATIVI E DEL PROFILO LIPIDICO IN PAZIENTI TRATTATI CON SULOCTIDIL
AU - Palmieri, G.
AU - Perego, M.
AU - Baldini, I. M.
PY - 1982
Y1 - 1982
N2 - A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.
AB - A double-blind clinical trial (Suloctidyl versus placebo) was carried out to determine changes in platelet aggregation, anti-thrombin III, partial thromboplastin time, triglycerides, cholesterol, and HDL cholesterol induced by 300 mg/day active principle for 30 days in 40 patients with coronary, peripheral, and cerebral atherosclerosis and hyperlipoproteinaemia. The drug led to a decrease in platelet aggregation, and a positive change in the HDL:LDL (antiatherogen:atherogen) ratio, but did not alter antithrombin III or the partial thromboplastin time.
UR - http://www.scopus.com/inward/record.url?scp=0020324693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020324693&partnerID=8YFLogxK
M3 - Articolo
VL - 141
SP - 143
EP - 152
JO - Gazzetta Medica Italiana Archivio per le Scienze Mediche
JF - Gazzetta Medica Italiana Archivio per le Scienze Mediche
SN - 0393-3660
IS - 4
ER -